Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Feasibility of chemoradiation with trastuzumab and pertuzumab in resectable HER2-positive esophageal carcinoma
2013-004111-42Phase 2Completed
- Sponsor
- Academic Medical Center
- Start
- Jan 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab, pertuzumab, carboplatin and paclitaxel in esophageal adenocarcinoma (EAC), gastroesophageal junction adenocarcinoma and esophageal cancer, sponsored by Academic Medical Center. Primary endpoint: Feasibility of preoperative treatment. Started Jan 2014; status: completed.
02
Drugs
03
Conditions
esophageal adenocarcinoma (EAC)gastroesophageal junction adenocarcinomaesophageal cancer
Beyond the preview
Go deeper on 2013-004111-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004111-42.